Congress creates public health plan, forces providers to participate, negotiates drug prices
S. 3369 — Medicare-X Choice Act of 2025 · Filed by Michael Bennet (D-CO) · 10 cosponsors · Introduced Dec 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new public health insurance plan called Medicare-X that would be available to individuals and small businesses starting in 2028, operating through existing ACA exchanges. The plan would reimburse providers at Medicare rates, negotiate drug prices, and include free primary care; it is funded with $2 billion in startup appropriations and would be self-sustaining through premiums. The bill also expands ACA tax credits, allows Medicare to negotiate drug prices more broadly, funds antitrust enforcement in health care, and establishes a reinsurance program to stabilize individual market premiums.
Why we flagged it
The bill's core mechanism is establishing a government-run health plan competing in private exchanges, combined with expanded Medicare drug negotiation authority and antitrust enforcement. This is fundamentally a public option proposal with ancillary cost-control measures, not a narrow carve-out or subsidy.
What the text implies
- Mandatory provider participation requirement (Section 2208) forces Medicare and Medicaid providers to accept the public plan or lose federal program enrollment—a significant leverage mechanism that may face legal challenge and could reshape provider networks.
- Risk-pool structure (Section 2206) creates state-level single risk pools that may concentrate high-cost patients, potentially destabilizing premiums if enrollment skews sicker; the bill's reinsurance program (Section 4) is limited to 2028–2030 and may not be permanent.
The full analysis lists 5 implications of this text.
Who stands to gain
Individual consumers (lower premiums, free primary care, expanded subsidies); Small businesses (access to competitive plan option); Generic and biosimilar manufacturers (drug price negotiation may favor lower-cost alternatives)